Modus Therapeutics Investor Relations Material
Latest events
Q4 2024
Modus Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Modus Therapeutics Holding
Access all reports
Modus Therapeutics AB is a healthcare company engaged in the development of drugs for rare diseases. Its product Slevaoxin, is focused on alleviating the elevated levels of neutrophil extracellular traps, which could reduce the widespread damage to organs and tissues, and frequently leads to life-threatening organ failure and death. It also develops MPC-06-ID, a drug candidate to address infantile onset Idiopathic nephrotic syndrome in children below the age of 2.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
MODTX
Country
🇸🇪 Sweden